Council withdraws diabetes medicine

07 July 2011 - 01:45 By HARRIET MCLEA
subscribe Just R20 for the first month. Support independent journalism by subscribing to our digital news package.
Subscribe now

The Medicines Control Council has withdrawn the diabetes medicine Avandia from the market because it contains a substance that might increase the likelihood of a heart attack.

The medication, produced by GlaxoSmithKline, is prescribed to some type2 diabetics.

The council made the decision five weeks ago "due to safety risks" attributed to rosiglitazone, a constituent of Avandia.

A statement by the council on Tuesday said: "Rosiglitazone is associated with an increased risk [of] heart failure, myocardial infarction [heart attack] and cardiac arrest".

Avandia was registered in South Africa in October 2004. The EU and the UK have already withdrawn rosiglitazone-containing medicine from their markets.

Spokesman for the department of health Fidel Hadebe could not say how many South Africans take Avandia.

"Given the reality that diabetes is a huge problem in South Africa, it is obvious that quite a number of people are on [Avandia]," he said.

Diabetes nurse educator Razana Allie, of Diabetes SA, said Metformin was one of a few alternative products that could be used in South Africa.

The local representatives of GlaxoSmithKline could not be reached for comment.

subscribe Just R20 for the first month. Support independent journalism by subscribing to our digital news package.
Subscribe now